Skip to content

Not yet independently audited

This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.

Pharmacologic treatment

TL;DR — Short-term symptom efficacy is best established for stimulants, but average rankings do not determine the best drug for an individual (Cortese 2018, PMID 30097390). In a network meta-analysis of 133 double-blind RCTs, amphetamines were favored for adults and methylphenidate for children/adolescents when efficacy and tolerability were jointly considered. Atomoxetine and alpha-2 agonists provide nonstimulant options with different onset and adverse-effect profiles (Radonjić 2023, PMID 37166701; Newcorn 2013, PMID 23972694). Evidence for long-term functional outcomes is less secure than acute rating-scale change (Swanson 2008, PMID 18573923). Centanafadine, a triple reuptake inhibitor, was FDA-approved on 24 July 2026 on placebo-controlled evidence of small-to-moderate effect (pooled g −0.37) with no head-to-head trials (Hu 2026, PMID 42640319; Muneer 2026, PMID 42267239).

Comparative evidence

Class Main role Common monitoring domains Evidence boundary
Methylphenidate First-line stimulant in many pediatric guidelines appetite, growth, sleep, pulse, BP Long-term RCT evidence limited
Amphetamines High acute efficacy; often favored in adults appetite, sleep, cardiovascular, misuse Acceptability varies (Cortese 2018, PMID 30097390)
Atomoxetine Nonstimulant; slower onset GI effects, BP/pulse, mood Smaller average acute effect
Guanfacine/clonidine Alpha-2 agonists, mainly pediatric sedation, hypotension, pulse Fewer adult data (Newcorn 2013, PMID 23972694)
Bupropion and others Off-label/context-specific drug-specific Evidence less extensive

The 2018 network meta-analysis included 133 double-blind randomized trials and separated clinician from teacher ratings and tolerability from efficacy. It supports population-average starting points, not deterministic sequencing (Cortese 2018, PMID 30097390).

Safety ledger

Large observational synthesis found no statistically significant overall association between ADHD medication and cardiovascular disease across ages, while not excluding a modest increase—especially cardiac arrest/tachyarrhythmia—and identifying uncertainty for females, pre-existing disease and long exposure (Zhang 2022, PMID 36416824).

Growth synthesis of 18 long-term methylphenidate studies (4,868 participants) found small reductions in height and weight z scores, most evident earlier in treatment (Carucci 2021, PMID 33080250).

Centanafadine: a new approved agent (sweep 2026-10-12)

Centanafadine (Simtriyo) is a norepinephrine-preferring norepinephrine–dopamine–serotonin reuptake inhibitor (potency NET > DAT > SERT) that blocks transporters without triggering monoamine release. The US FDA approved it on 24 July 2026 for ADHD in adults and in patients aged ≥6 years weighing ≥20 kg. The label carries boxed warnings for abuse, misuse and addiction and for pediatric suicidal ideation/behaviour, contraindicates MAO-inhibitor co-use, and DEA scheduling was still pending when the source was written (Hu 2026, PMID 42640319; approval date, label warnings and scheduling status read from the PMC full text).

Evidence Population Result Boundary
Two adult phase 3 RCTs, 6 weeks 18–55 y, n≈876 randomized AISRS LS-mean difference −2.74 to −4.47; effect sizes −0.24 to −0.40 (Adler 2022, PMID 35652746) Small effects; placebo comparator only
Adolescent phase 3 RCT (NCT05257265), 6 weeks, no titration 13–17 y, n=459 328.8 mg beat placebo on ADHD-RS-5 (−18.50 vs −14.15); 164.4 mg failed the primary endpoint; TEAEs 50.3% vs 23.8% placebo (Ward 2026, PMID 40619095; erratum published) Fixed dose; short
Pediatric programme secondary analysis (NCT05428033, NCT05257265) 6–17 y Low dose failed the primary endpoint and was excluded from secondary analyses (Ward 2026, PMID 42779129) Sponsor secondary analysis
Meta-analysis 5 RCTs, n=1,968 Hedges' g −0.37 (95% CI −0.68 to −0.05); CGI-S MD −0.26; any-AE RR 1.29 (0.97–1.71) (Muneer 2026, PMID 42267239) Placebo-only network

Regulatory follow-up, 2026-10-19. OIRA lists DEA rule RIN 1117-ZA11, “Placement of Centanafadine in Schedule III,” received 14 October 2026 and marked “Pending Review” at the interim-final-rule stage. This records an intended Schedule III placement under review; it does not establish an effective scheduling date (OIRA/Reginfo.gov — “Schedules of Controlled Substances: Placement of Centanafadine in Schedule III”, https://www.reginfo.gov/public/do/eo/neweomeeting?rin=1117-ZA11, accessed 2026-10-19).

Unresolved classification. The meta-analysis frames centanafadine as a non-stimulant (Muneer 2026, PMID 42267239), the pediatric secondary report calls it a central nervous system stimulant (Ward 2026, PMID 42779129), and the label carries an abuse boxed warning with scheduling pending (Hu 2026, PMID 42640319). Its place in sequencing therefore cannot be read from the word "non-stimulant". Of the 36 PubMed records for "centanafadine" (all dates, searched 2026-10-12), none is a head-to-head randomized trial against an established ADHD medication; comparative claims rest on matching-adjusted indirect comparisons. This is an absence in PubMed only.

Titration and outcome definition

Dose is titrated to a predeclared balance of symptom and functional benefit against harms. A lower symptom score without better function, or with unacceptable sleep/appetite effects, is not an unqualified success.

Safety signals added 2026-10-12

  • Amphetamines and blood pressure (Cochrane). Across 56 RCTs (10,583 participants, ADHD and other indications), daily oral amphetamines raised systolic BP by 1.93 mmHg (95% CI 1.54–2.31), diastolic BP by 1.84 mmHg (1.51–2.16) and heart rate by 3.71 bpm (3.27–4.14), all high-certainty. Effects were similar in trials lasting ≥8 weeks, and withdrawals for adverse effects rose (RR 2.69, 2.13–3.40) (Chan 2025, PMID 40152309). These are average haemodynamic shifts. They are not event rates, so they sit alongside the null-to-modest event-level synthesis above rather than contradicting it (Zhang 2022, PMID 36416824).
  • Adult noradrenaline reuptake inhibitors. A GRADE-based review of 21 RCTs (5,124 adults) judged that NRIs "may have little to no effect" on daily functioning, symptoms and quality of life, and estimated atomoxetine serious adverse events at RR 2.31 (1.79–2.97, moderate certainty) (Nurkhametova 2026, PMID 42751977). This benefit–harm judgement is more negative than the meta-analytic literature on adult nonstimulants (Radonjić 2023, PMID 37166701), and the disagreement is unresolved. The serious-AE definition was read from the abstract only.
  • Pre-existing cardiometabolic disease. In a seven-country cohort of 1,929,027 adults with type 2 diabetes, ADHD medication use was not associated with MACE overall but was associated with it when T2D was diagnosed before age 45 (HR 1.58, 1.18–2.10) (Dong 2026, PMID 42806384). This is a subgroup signal relevant to OQ-5.
  • Self-harm. A five-site self-controlled case series (461,024 medication users; 6,847 incident self-harm events) found the highest risk in the 90 days before initiation (IRR 2.58, 2.12–3.13), then 1.78 (1.23–2.57) in the first 90 days of use and 1.27 (1.01–1.60) thereafter. The authors read this as not supporting medication as the main driver (Chan 2026, PMID 42731881). See red flags.

Long-term interpretation

After the MTA randomized phase, treatment convergence and naturalistic selection weakened causal comparisons. Long-term observational associations should be read with confounding by severity, access and adherence in mind (Swanson 2008, PMID 18573923).

How to read the evidence

  • Diagnostic case–control separation is not the same as accuracy among referred patients.
  • Symptom change is not interchangeable with functional improvement.
  • Short randomized trials estimate acute efficacy, not decades-long benefit or harm.
  • Observational within-person and target-trial designs reduce some confounding but remain nonrandomized.
  • Parent, teacher, clinician, self-report and objective tasks measure different vantage points.
  • Statistical significance does not establish a patient-important effect.
  • Population averages should not be converted into deterministic individual predictions.
  • Absence of evidence in a subgroup is not evidence of identical effects.

Minimum standards for the next evidence generation

  1. Prespecify one primary outcome and its clinically important threshold.
  2. Report symptoms, function, quality of life and harms separately.
  3. Use clinically relevant comparators rather than only healthy controls.
  4. Retain and report participants who discontinue treatment.
  5. Test generalization across sex, age, ancestry, comorbidity and setting.
  6. Separate model development, internal validation and external validation.
  7. Declare medication exposure, concomitant care and rater blinding.
  8. Make null and contradictory results visible rather than averaging away design differences.

Recurring evidence gaps

  • Females, older adults and people with complex comorbidity remain underrepresented.
  • Functional outcomes are measured less consistently than core symptoms.
  • Follow-up usually ends before major educational or occupational transitions.
  • Comparator choice often makes effects look more or less specific than they are.
  • Treatment discontinuation and switching weaken long-term causal contrasts.
  • Independent replication is uncommon for biomarkers and digital interventions.

Retrieved evidence map

The following records were retrieved through this page’s six live PubMed searches. Inclusion here means the record is directly relevant to the page’s scope; it does not imply equal quality or endorsement of its conclusions.

Citation Indexed study lens Directly studied question/title Interpretation boundary
Cortese 2018, PMID 30097390 Comparative Study, Journal Article Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Interpret within its sampled population and comparator
Radonjić 2023, PMID 37166701 Systematic Review, Research Support, Non-U.S. Gov't Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis. Interpret within its sampled population and comparator
Newcorn 2013, PMID 23972694 Comparative Study, Journal Article Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. Interpret within its sampled population and comparator
Swanson 2008, PMID 18573923 Consensus Statement, Journal Article Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Interpret within its sampled population and comparator
Zhang 2022, PMID 36416824 Meta-Analysis, Systematic Review Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. Interpret within its sampled population and comparator
Carucci 2021, PMID 33080250 Journal Article, Meta-Analysis Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. Interpret within its sampled population and comparator
Ostinelli 2025, PMID 39701638 Comparative Study, Journal Article Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Interpret within its sampled population and comparator
Nourredine 2026, PMID 42134365 Journal Article, Systematic Review Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis. Interpret within its sampled population and comparator
Bellato 2025, PMID 38823477 Journal Article, Systematic Review Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life. Interpret within its sampled population and comparator
Elliott 2020, PMID 33085721 Journal Article, Research Support, Non-U.S. Gov't Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. Interpret within its sampled population and comparator
Catalá-López 2017, PMID 28700715 Journal Article, Systematic Review The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. Interpret within its sampled population and comparator
Farhat 2025, PMID 40203844 Journal Article, Systematic Review Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Interpret within its sampled population and comparator
Nourredine 2024, PMID 39396049 Journal Article, Research Support, Non-U.S. Gov't Efficacy of pharmacological interventions for ADHD: protocol for an updated systematic review and dose-response network meta-analysis. Interpret within its sampled population and comparator
Pan 2022, PMID 34635194 Systematic Review, Journal Article Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis. Interpret within its sampled population and comparator
Solmi 2020, PMID 32394557 Journal Article Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. Interpret within its sampled population and comparator
Jaeschke 2021, PMID 34436651 Journal Article, Review Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review. Interpret within its sampled population and comparator
Storebø 2023, PMID 36971690 Systematic Review, Journal Article Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Interpret within its sampled population and comparator
Salazar de Pablo 2025, PMID 40900605 Journal Article, Systematic Review Occurrence of Psychosis and Bipolar Disorder in Individuals With Attention-Deficit/Hyperactivity Disorder Treated With Stimulants: A Systematic Review and Meta-Analysis. Interpret within its sampled population and comparator
Gillies 2023, PMID 37058600 Systematic Review, Journal Article Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Interpret within its sampled population and comparator
Osland 2018, PMID 29944175 Journal Article, Research Support, Non-U.S. Gov't Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Interpret within its sampled population and comparator
Boesen 2017, PMID 28705922 Journal Article The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. Interpret within its sampled population and comparator
Kittel-Schneider 2021, PMID 33516734 Journal Article, Research Support, Non-U.S. Gov't Parental ADHD in pregnancy and the postpartum period - A systematic review. Interpret within its sampled population and comparator
Gosling 2025, PMID 41297970 Journal Article, Systematic Review Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making. Interpret within its sampled population and comparator
Lenzi 2018, PMID 28837827 Journal Article, Meta-Analysis Pharmacotherapy of emotional dysregulation in adults with ADHD: A systematic review and meta-analysis. Interpret within its sampled population and comparator
Brunkhorst-Kanaan 2021, PMID 33582234 Journal Article, Research Support, Non-U.S. Gov't ADHD and accidents over the life span - A systematic review. Interpret within its sampled population and comparator
Hennissen 2017, PMID 28236285 Journal Article, Meta-Analysis Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. Interpret within its sampled population and comparator
Wilens 2008, PMID 18174822 Journal Article, Research Support, N.I.H., Extramural Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. Interpret within its sampled population and comparator
Isfandnia 2024, PMID 38718988 Journal Article, Meta-Analysis The effects of chronic administration of stimulant and non-stimulant medications on executive functions in ADHD: A systematic review and meta-analysis. Interpret within its sampled population and comparator
Pringsheim 2015, PMID 25886655 Journal Article, Meta-Analysis The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Interpret within its sampled population and comparator
Terao 2024, PMID 38069471 Systematic Review, Meta-Analysis The Dose-Response Relationship of Atomoxetine for the Treatment of Children With ADHD: A Systematic Review and Dose-Response Meta-Analysis of Double-Blind Randomized Placebo-Controlled Trials. Interpret within its sampled population and comparator
Sharma 2014, PMID 24259638 Journal Article, Review A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Interpret within its sampled population and comparator
Martins 2024, PMID 39004333 Systematic Review, Journal Article Effectiveness of pharmacological interventions for managing ADHD symptoms in individuals with autism spectrum disorder: A systematic review and meta-analysis. Interpret within its sampled population and comparator

Open questions

  • Can baseline clinical features predict stimulant versus nonstimulant benefit? (Cortese 2018, PMID 30097390)
  • What are cardiovascular effects beyond a decade in higher-risk subgroups? (Zhang 2022, PMID 36416824)
  • Which medication strategies causally improve education, work and relationships? (Swanson 2008, PMID 18573923)

References

  1. Cortese et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The lancet. Psychiatry. 2018;5:727-738. PMID 30097390
  2. Radonjić et al. Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis. CNS drugs. 2023;37:381-397. PMID 37166701
  3. Newcorn et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. Journal of the American Academy of Child and Adolescent Psychiatry. 2013;52:921-30. PMID 23972694
  4. Swanson et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Journal of attention disorders. 2008;12:4-14. PMID 18573923
  5. Zhang et al. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. JAMA network open. 2022;5:e2243597. PMID 36416824
  6. Carucci et al. Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. Neuroscience and biobehavioral reviews. 2021;120:509-525. PMID 33080250
  7. Ostinelli et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The lancet. Psychiatry. 2025;12:32-43. PMID 39701638
  8. Nourredine et al. Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis. The lancet. Psychiatry. 2026;13:485-495. PMID 42134365
  9. Bellato et al. Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life. Journal of the American Academy of Child and Adolescent Psychiatry. 2025;64:346-361. PMID 38823477
  10. Elliott et al. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. PloS one. 2020;15:e0240584. PMID 33085721
  11. Catalá-López et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PloS one. 2017;12:e0180355. PMID 28700715
  12. Farhat et al. Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The lancet. Psychiatry. 2025;12:355-365. PMID 40203844
  13. Nourredine et al. Efficacy of pharmacological interventions for ADHD: protocol for an updated systematic review and dose-response network meta-analysis. Systematic reviews. 2024;13:256. PMID 39396049
  14. Pan et al. Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis. Psychological medicine. 2022;52:14-25. PMID 34635194
  15. Solmi et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World psychiatry : official journal of the World Psychiatric Association (WPA). 2020;19:214-232. PMID 32394557
  16. Jaeschke et al. Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review. Psychopharmacology. 2021;238:2667-2691. PMID 34436651
  17. Storebø et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). The Cochrane database of systematic reviews. 2023;3:CD009885. PMID 36971690
  18. Salazar de Pablo et al. Occurrence of Psychosis and Bipolar Disorder in Individuals With Attention-Deficit/Hyperactivity Disorder Treated With Stimulants: A Systematic Review and Meta-Analysis. JAMA psychiatry. 2025;82:1103-1112. PMID 40900605
  19. Gillies et al. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. The Cochrane database of systematic reviews. 2023;4:CD007986. PMID 37058600
  20. Osland et al. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. The Cochrane database of systematic reviews. 2018;6:CD007990. PMID 29944175
  21. Boesen et al. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. Evidence-based medicine. 2017;22:143-147. PMID 28705922
  22. Kittel-Schneider et al. Parental ADHD in pregnancy and the postpartum period - A systematic review. Neuroscience and biobehavioral reviews. 2021;124:63-77. PMID 33516734
  23. Gosling et al. Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making. BMJ (Clinical research ed.). 2025;391:e085875. PMID 41297970
  24. Lenzi et al. Pharmacotherapy of emotional dysregulation in adults with ADHD: A systematic review and meta-analysis. Neuroscience and biobehavioral reviews. 2018;84:359-367. PMID 28837827
  25. Brunkhorst-Kanaan et al. ADHD and accidents over the life span - A systematic review. Neuroscience and biobehavioral reviews. 2021;125:582-591. PMID 33582234
  26. Hennissen et al. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS drugs. 2017;31:199-215. PMID 28236285
  27. Wilens et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry. 2008;47:21-31. PMID 18174822
  28. Isfandnia et al. The effects of chronic administration of stimulant and non-stimulant medications on executive functions in ADHD: A systematic review and meta-analysis. Neuroscience and biobehavioral reviews. 2024;162:105703. PMID 38718988
  29. Pringsheim et al. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2015;60:42-51. PMID 25886655
  30. Terao et al. The Dose-Response Relationship of Atomoxetine for the Treatment of Children With ADHD: A Systematic Review and Dose-Response Meta-Analysis of Double-Blind Randomized Placebo-Controlled Trials. Journal of attention disorders. 2024;28:431-438. PMID 38069471
  31. Sharma et al. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). The Annals of pharmacotherapy. 2014;48:209-25. PMID 24259638
  32. Martins et al. Effectiveness of pharmacological interventions for managing ADHD symptoms in individuals with autism spectrum disorder: A systematic review and meta-analysis. Progress in neuro-psychopharmacology & biological psychiatry. 2024;134:111089. PMID 39004333
  33. Hu et al. Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD). Med Chem Res. 2026;35:1548-1552. PMID 42640319
  34. Adler et al. Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials. J Clin Psychopharmacol. 2022;42:429-439. PMID 35652746
  35. Ward et al. Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial. J Am Acad Child Adolesc Psychiatry. 2026;65:805-817. PMID 40619095
  36. Ward et al. Clinically Meaningful Within-Patient Change in Core Attention-Deficit/Hyperactivity Disorder Symptoms in Children and Adolescents Treated With Centanafadine: Results From Two Phase 3 Randomized Clinical Trials. J Atten Disord. 2026:10870547261483444. PMID 42779129
  37. Muneer et al. Efficacy and Safety of Centanafadine in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Psychopharmacol Bull. 2026;56:47-65. PMID 42267239
  38. Chan et al. Effect of amphetamines on blood pressure. Cochrane Database Syst Rev. 2025;3:CD007896. PMID 40152309
  39. Nurkhametova et al. Noradrenaline reuptake inhibitors (NRIs) for attention deficit hyperactivity disorder (ADHD) in adults. Int J Risk Saf Med. 2026:9246479261461033. PMID 42751977
  40. Dong et al. Major adverse cardiac events and mortality associated with ADHD and its treatment in adults with type 2 diabetes: a multi-national cohort study. BMC Med. 2026;24:527. PMID 42806384
  41. Chan et al. ADHD medication use and risk of self-harm: a multinational self-controlled case series study. BMJ Ment Health. 2026;29:e302819. PMID 42731881

OIRA/Reginfo.gov. Schedules of Controlled Substances: Placement of Centanafadine in Schedule III. RIN 1117-ZA11. https://www.reginfo.gov/public/do/eo/neweomeeting?rin=1117-ZA11 (accessed 2026-10-19).